IBOV 170,888.18 ▼ 0.91% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.75▲ 1.47% USD/MXN18.66▲ 0.79% USD/CLP1,002▲ 0.76% USD/COP3,316▲ 0.41% USD/PEN3.41▲ 0.33% USD/ARS1,550▲ 0.40% USD/UYU40.61▲ 0.05% USD/PYG6,186▼ 0.16% USD/BOB 11.59 — 0.00% USD/DOP60.36▼ 0.38% USD/CRC442.56▼ 0.04% USD/GTQ7.64▼ 0.05% USD/HNL26.90▼ 0.05% USD/NIO 36.62 — 0.00% USD/VES911.74▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.99▲ 0.19% USD/TTD6.72▼ 0.44% EUR/BRL6.33▲ 1.29% BRENT 93.82 ▼ 2.11% WTI 87.06 ▼ 1.69% IRON ORE 161.91 — — COPPER 6.05 ▼ 0.48% GOLD 3,884 ▼ 0.06% SILVER 47.08 ▼ 3.99% SOY 1,227 ▼ 1.29% CORN 444.50 ▼ 0.22% WHEAT 588.25 ▼ 0.84% COFFEE 276.30 ▼ 0.84% SUGAR 18.28 ▼ 0.71% ORANGE JUICE 138.70 ▲ 1.76% COTTON 81.34 ▲ 3.25% COCOA 5,216 ▲ 1.89% BEEF 219.08 ▼ 0.71% CATTLE 337.28 ▼ 0.52% LITHIUM 57.56 ▼ 2.04% PETR4 44.58 ▼ 1.59% VALE3 62.06 ▼ 2.27% ITUB4 41.65 ▼ 1.47% BBDC4 14.34 ▼ 1.24% ABEV3 15.87 ▲ 0.51% BBAS3 14.62 ▼ 3.18% B3SA3 14.68 ▼ 1.41% WEGE3 50.52 ▼ 1.54% PRIO3 62.77 ▼ 0.84% SUZB3 54.92 ▲ 0.27% RENT3 29.41 ▼ 2.19% AZZA3 15.84 ▼ 0.44% CSAN3 3.02 ▼ 2.58% RAIZ4 20.00 — 0.00% PCAR3 2.46 ▼ 3.91% GMAT3 4.18 ▼ 1.65% PSSA3 45.48 ▼ 2.00% CVCB3 0.79 ▼ 4.82% POSI3 3.07 ▼ 2.54% SLCE3 17.92 ▼ 1.97% NATU3 4.84 ▼ 5.65% BRKM5 2.90 ▼ 3.97% RANI3 8.13 ▼ 0.61% CSNA3 3.71 ▼ 0.27% IBOV 170,888.18 ▼ 0.91% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.75 ▲ 1.44% USD/MXN 18.66 ▲ 0.81% USD/CLP 1,002 ▲ 0.71% USD/COP 3,316 ▲ 0.41% USD/PEN 3.41 ▲ 0.34% USD/ARS 1,550 ▲ 0.40% USD/UYU 40.61 ▲ 0.05% USD/PYG 6,186 ▼ 0.16% USD/BOB 11.59 — 0.00% USD/DOP 60.36 ▼ 0.38% USD/CRC 442.56 ▼ 0.04% USD/GTQ 7.64 ▼ 0.05% USD/HNL 26.90 ▼ 0.05% USD/NIO 36.62 — 0.00% USD/VES 911.74 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.99 ▲ 2.95% USD/TTD 6.72 ▲ 2.12% EUR/BRL 6.33 ▲ 1.30% BRENT 93.82 ▼ 2.11% WTI 87.06 ▼ 1.69% IRON ORE 161.91 — — COPPER 6.05 ▼ 0.48% GOLD 3,884 ▼ 0.06% SILVER 47.08 ▼ 3.99% SOY 1,227 ▼ 1.29% CORN 444.50 ▼ 0.22% WHEAT 588.25 ▼ 0.84% COFFEE 276.30 ▼ 0.84% SUGAR 18.28 ▼ 0.71% ORANGE JUICE 138.70 ▲ 1.76% COTTON 81.34 ▲ 3.25% COCOA 5,216 ▲ 1.89% BEEF 219.08 ▼ 0.71% CATTLE 337.28 ▼ 0.52% LITHIUM 57.56 ▼ 2.04% PETR4 44.58 ▼ 1.59% VALE3 62.06 ▼ 2.27% ITUB4 41.65 ▼ 1.47% BBDC4 14.34 ▼ 1.24% ABEV3 15.87 ▲ 0.51% BBAS3 14.62 ▼ 3.18% B3SA3 14.68 ▼ 1.41% WEGE3 50.52 ▼ 1.54% PRIO3 62.77 ▼ 0.84% SUZB3 54.92 ▲ 0.27% RENT3 29.41 ▼ 2.19% AZZA3 15.84 ▼ 0.44% CSAN3 3.02 ▼ 2.58% RAIZ4 20.00 — 0.00% PCAR3 2.46 ▼ 3.91% GMAT3 4.18 ▼ 1.65% PSSA3 45.48 ▼ 2.00% CVCB3 0.79 ▼ 4.82% POSI3 3.07 ▼ 2.54% SLCE3 17.92 ▼ 1.97% NATU3 4.84 ▼ 5.65% BRKM5 2.90 ▼ 3.97% RANI3 8.13 ▼ 0.61% CSNA3 3.71 ▼ 0.27%
since 2009
Monday, November 16, 2026

Brazil Business - Brazil

Novo Nordisk Commits $1.12 Billion to Expand Ozempic Production in Brazil

By · · 2 min read

Novo Nordisk, the Danish pharmaceutical leader, announced a R$6.4 billion ($1.12 billion) investment in its Montes Claros facility in Minas Gerais, Brazil.

This expansion aims to double the plant’s size and enhance production capacity for diabetes and obesity treatments, including its blockbuster drugs Ozempic and Wegovy.

The announcement, made on April 7, 2025, was attended by Brazilian President Luiz Inácio Lula da Silva and other top officials. The investment will add 74,000 square meters to the site, with operations in the new section expected to launch by 2028.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

Novo Nordisk plans to create 600 new jobs, adding to its current workforce of over 2,000 employees in Brazil. The facility already plays a critical role in the company’s global supply chain, producing 12% of the world’s insulin and exporting it to over 70 countries.

This marks Novo Nordisk’s third major investment in Montes Claros within two years. In October 2024, the company allocated R$864 million ($152 million) to modernize insulin production and implement sustainability projects.

Novo Nordisk Commits $1.12 Billion to Expand Ozempic Production in Brazil
Novo Nordisk Commits $1.12 Billion to Expand Ozempic Production in Brazil.
RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Two months later, it injected another R$500 million ($88 million) into enzyme production for semaglutide-based drugs like Ozempic and Wegovy. The company’s decision underscores Brazil’s strategic importance within its global operations.

Novo Nordisk Expands in Brazil

The Montes Claros plant not only supplies insulin for Brazil’s public health system but also contributes significantly to pharmaceutical exports, accounting for 25% of all medicines exported from the country.

Novo Nordisk’s growth coincides with surging demand for its diabetes and weight-loss drugs. Wegovy sales alone rose by 79% in Q3 2024, generating $2.3 billion in revenue.

However, competition is heating up as Ozempic’s patent expires in 2026. Brazilian firms like EMS are already developing generic versions of semaglutide, while Eli Lilly plans to introduce its rival drug Mounjaro this year.

Despite uncertainties about pricing and production specifics at the expanded facility, Novo Nordisk emphasizes that this investment will bring cutting-edge treatments closer to Brazilian patients while bolstering the country’s pharmaceutical sector.

This move also aligns with the company’s sustainability goals, as the Montes Claros plant integrates renewable energy and waste recycling into its operations.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.